This is pretty good too imo..
"During the period from March 30, 2015 to December 31, 2016, the Company had completed sales to Aspire totaling 8.2 million shares of common stock generating gross proceeds of approximately $11 million."
Planning to spend $19M in 1 year is pretty aggressive.
"The Company plans to incur expenses of approximately $19 million over the next twelve months, including approximately $15 million for clinical trials."
We need the cash position for many reasons so it will be very interesting if we can swing a partnership this summer. $45M on the shelf is decent but it's clear they will do something to make sure they have the cash for the future. A partnership can go a long way there, hopefully before a raise. I'm thinking we'll be seeing the PRE-14 in the next month or so that may spell out their plans.
sorry for the edits.
"During the period from March 30, 2015 to December 31, 2016, the Company had completed sales to Aspire totaling 8.2 million shares of common stock generating gross proceeds of approximately $11 million."
Planning to spend $19M in 1 year is pretty aggressive.
"The Company plans to incur expenses of approximately $19 million over the next twelve months, including approximately $15 million for clinical trials."
We need the cash position for many reasons so it will be very interesting if we can swing a partnership this summer. $45M on the shelf is decent but it's clear they will do something to make sure they have the cash for the future. A partnership can go a long way there, hopefully before a raise. I'm thinking we'll be seeing the PRE-14 in the next month or so that may spell out their plans.
sorry for the edits.
2
